Balyasny Asset Management
CUE icon

Balyasny Asset Management’s Cue Biopharma CUE Stock Holding History

Balyasny Asset Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-358
Closed -$13.3K – 2807
2024
Q2 		$13.3K Buy
+358
New +$17.7K ﹤0.01% 2486

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
GLA
Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Balyasny Asset Management's CUE Position: Q3 2024 in Review

Balyasny Asset Management sold out of Cue Biopharma (CUE) in Q3 2024, closing a stake of 358 shares — an estimated $13.3K sold.

Balyasny Asset Management first reported a position in CUE in Q2 2024 and held it in 1 quarter. The position peaked at $13.3K in Q2 2024. 50 funds tracked by Wall St. Rank hold CUE as of Q3 2024.

  • Balyasny Asset Management reported no remaining Cue Biopharma position as of Q3 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 358 Cue Biopharma shares in Q3 2024, an estimated $13.3K.
  • Balyasny Asset Management first reported a position in Cue Biopharma in Q2 2024 and held it in 1 quarter.
  • Balyasny Asset Management's Cue Biopharma position peaked at $13.3K in Q2 2024.
  • 50 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2024.

Based on Balyasny Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.